Compounds having mif antagonist activity
Номер патента: EP1311255A1
Опубликовано: 21-05-2003
Автор(ы): Peter Senter, Richard J. Bucala, Robert A. Mitchell, Yousef Al-Abed
Принадлежит: Picower Institute for Medical Research
Опубликовано: 21-05-2003
Автор(ы): Peter Senter, Richard J. Bucala, Robert A. Mitchell, Yousef Al-Abed
Принадлежит: Picower Institute for Medical Research
Реферат: There are disclosed methods of use and pharmaceutical compositions for two related fenera of low molecular weight compounds comprising optionally substituted iminoquinone or orthoquinone ring systems. The compounds have MIF (macrophage migration inhibitory factor) antagonist activity and find utility as such. For example, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, EAE, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular diseases, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).
Compounds having mif antagonist activity
Номер патента: EP1311255A4. Автор: Peter Senter,Yousef Al-Abed,Richard J Bucala,Robert A Mitchell. Владелец: Picower Institute for Medical Research. Дата публикации: 2008-07-09.